Fortress Biotech, Inc. - Jan 5, 2023 Form 4 Insider Report for Checkpoint Therapeutics, Inc. (CKPT)

Role: 10%+ Owner
Signature: /s/ Samuel Berry, General Counsel and Authorized Agent
Stock symbol: CKPT
Transactions as of: Jan 5, 2023
Transactions value $: $0
Form type: 4
Date filed: 1/6/2023, 04:57 PM
Previous filing: Jan 4, 2023
Next filing: Jan 6, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CKPT	COMMON STOCK, PAR VALUE $0.0001	Award	$0	+369K	+32.51%	$0.00	1.5M	Jan 5, 2023	Direct	F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	CKPT	Class A Common Stock, par value $0.0001						700K	Jan 5, 2023	Common Stock	700K		Direct	F2, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person is entitled to an annual equity fee grant from the issuer of a number of shares of the Issuer's Common Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on December 31. These shares were granted by the Issuer to the Reporting Person for the 2022 annual equity fee grant.
F2	Effective December 6, 2022, the Issuer effected a one-for-ten reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split.
F3	The total number of shares beneficially owned by the Reporting Person includes those transactions as disclosed on the table filed herewith as Exhibit 99.
F4	Each share of the Issuer's Class A Preferred Stock is convertible at any time at the option of the Reporting Person into one share of the Issuer's Common Stock and has no expiration date.